

Raynar Flagship

Sub Fund of : EFG Silverstone SICAV-RAIF

Factsheet

August 2020

Fund Manager:



Portfolio Manager:
Philip Rodriqs

First Day of Trading:
1 June 2020

Fund Assets Under
Management:
£20.4m

Firm Assets Under
Management
£56.5m

Custodian:
EFG Bank (Luxembourg) S.A.

AIFM
EFG Fund Management S.A.


Administrator:
HSBC France,
Luxembourg Branch

Auditor:
BDO Audit S.A. Luxembourg

Fund Objective:

To achieve capital growth over the medium term with an absolute focus on stock selection, unconstrained in its approach to building a high conviction portfolio of attractive risk vs return high conviction investments from across the UK equity market, with a likely predominance of small and micro sized companies. During periods with insufficient opportunities, unallocated capital will be preserved utilising the flexibility to invest in cash, beta hedging instruments and other asset classes.

FOR PROFESSIONAL INVESTORS ONLY



	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Cumulative Return
2019									-0.43%	-0.39%	4.67%	4.14%	8.11%
2020	1.78%	-9.22%	-4.11%	23.88%	9.77%	3.57%	6.50%	7.80%					43.25%

Past performance is not a reliable indicator of future performance.

*Raynar Flagship performance in dark blue shows the net asset values of Class A Distribution shares in GBP from launch sourced from Bloomberg net of all fees and costs. Past performance from 1st August 2019 to 29th May 2020 shown in light blue is an illustrative scenario. Using Bloomberg, actual weights of holdings and cash held by Raynar Flagship as at end of June 2020 have been applied to the start date of 1st July 2019 and a performance simulation of that portfolio generated, with the same fee and cost structure applied, rebased to 100 as of 29th May 2020.

Raynar Flagship

Factsheet
August 2020

Sub Fund of : EFG Silverstone SICAV-RAIF

Top Ten Equities	Holding
MaxCyte	7.2%
LoopUp	7.0%
Gear4Music	5.5%
CentralNic	4.8%
Gamesys	4.6%
Purplebricks	4.3%
Avacta	4.3%
BigBlu Broadband	4.2%
Kape Technologies	3.3%
FRP Advisory	3.1%

Top Ten Investment Themes	Allocation
Internet Enabled Retail/Services	20.2%
Capital Preservation	14.8%
Medical Technology	14.7%
Home Working Connectivity	14.0%
Internet Utilities	8.2%
Recession Beneficiaries	7.7%
Gold and Gold Miners	7.6%
Market Volatility Beneficiaries	3.9%
Government Stimulus Beneficiaries	3.5%
Eating In Beneficiaries	2.8%

MaxCyte

A valuable investment maxim is to avoid investment propositions that 'sound too good to be true'. But sometimes there are exceptions that prove that rule, and **MaxCyte** is a top holding on that premise.

In recent decades there have been waves of innovation as fundamental new discoveries lead to major new classes of treatments. At the cutting edge is a new method which uses a patient's own blood cells to fight disease. By taking a patient's own blood, inserting a drug or a DNA instruction into tens of millions of those blood cells and returning them to the patient (with much reduced rejection risk), the patient's own cells can fight disease. Despite sounding like science fiction, early examples of this new class of therapy are producing very significant results.

So how do you inject DNA instructions into millions of cells? Some use a modified virus, which takes many days. **MaxCyte's** unique and strongly patented Flow Electroporation technology can use electrical pulses to deliver the payload within a day – a game-changer that has seen **MaxCyte** sign up a succession of industry leaders to their roster. Can **MaxCyte** really have a globally significant medical technology platform that could enable countless therapies and cures? At £275m valuation (up over 100% since initial purchase) it may seem like this minnow could be too good to be true: however **MaxCyte** is held with the same degree of conviction as that demonstrated by the firm's customers.

Contact Details

Head of Client Relations:

Jon Garland

jon@raynarpm.com

T: 0207 1234 606

M: 0745 809 2791

Websites:

www.raynarpm.com

www.efg-fundmanagement.com

Enquiries Form:

www.raynarpm.com/investor-enquiries/

Raynar Flagship Share Classes	A Class	B Class
Inception Date	29 th May 2020	24 th August 2020
Status	Open	Open
Minimum Initial Investment	£200,000	£5,000,000
Subscription	Daily, zero fee	Daily, zero fee
Redemption	Monthly, zero fee	Monthly, zero fee
Redemption Notice	20 Business Days	20 Business Days
Annual Management Charge	1.00%	0.75%
Performance Fee	20%	20%
Hurdle Rate	5% per annum	10% per annum
High Water Mark	Yes – Lifetime	Yes – Lifetime
Distribution/Accumulation	Distribution	Distribution
ISIN	LU2076760391	LU2203806885
Bloomberg Ticker	EFSRFGI LX	EFSRFBG LX

All data correct as of the end of August 2020. Investment Themes are categorisations chosen by the portfolio manager which, in their opinion, best describes the predominant driver of the underlying investments in each category.

The investment strategies employed by Raynar Portfolio Management are intended only for those persons who may be categorised as professional clients. Raynar Portfolio Management is a trading name of Met Facilities LLP which is authorised and regulated by the Financial Conduct Authority (FRN: 587084). Met Facilities LLP is the investment manager of the Fund. EFG Fund Management SA is the Alternative Investment Fund Manager (AIFM).